{
    "nct_id": "NCT02726009",
    "official_title": "An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Has given written informed consent before any study-related activity is performed\n* Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon® is intended to be used for treatment\n* Age greater than or equal to 18 years and less than 80 years\n* Advanced hormone-dependent prostate cancer without any other clinically significant disorder\n* Easten Cooperative Oncology Group score ≤ 2\n* PSA ≥ 2 ng/mL at screening\n* Life expectancy of at least 12 months as per the investigator's judgement\n\nExclusion Criteria:\n\n* Previous or concurrent hormonal management of prostate cancer\n* Contraindication for prescription of Firmagon®\n* Concurrent treatment with a 5-α-reductase inhibitor\n* Considered as a candidate for curative therapy\n* History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema\n* QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications\n* Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin\n* Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment)\n* Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer\n* Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections\n\nsex: MALE\n\nminimumAge: 18 Years\n\nmaximumAge: 79 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Has given written informed consent before any study-related activity is performed\n* Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon® is intended to be used for treatment\n* Age greater than or equal to 18 years and less than 80 years\n* Advanced hormone-dependent prostate cancer without any other clinically significant disorder\n* Easten Cooperative Oncology Group score ≤ 2\n* PSA ≥ 2 ng/mL at screening\n* Life expectancy of at least 12 months as per the investigator's judgement",
        "exclusion": "* Previous or concurrent hormonal management of prostate cancer\n* Contraindication for prescription of Firmagon®\n* Concurrent treatment with a 5-α-reductase inhibitor\n* Considered as a candidate for curative therapy\n* History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema\n* QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications\n* Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin\n* Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment)\n* Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer\n* Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections"
    }
}